MicroRNA-122-functionalized DNA tetrahedron stimulate hepatic differentiation of human mesenchymal stem cells for acute liver failure therapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
As the most abundant liver-specific microRNA, microRNA-122 (miR122) played a crucial role in the differentiation of stem cells into hepatocytes. However, highly efficient miR122 delivery still confronts challenges including poor cellular uptake and easy biodegradation. Herein, we for the first time demonstrated that the tetrahedral DNA (TDN) nanoplatform had great potential in inducing the differentiation of human mesenchymal stem cells (hMSCs) into functional hepatocyte-like cells (HLCs) by transferring the liver-specific miR122 to hMSCs efficiently without any extrinsic factors. As compared with miR122, miR122-functionalized TDN (TDN-miR122) could significantly up-regulate the protein expression levels of mature hepatocyte markers and hepatocyte-specific marker genes in hMSCs, indicating that TDN-miR122 could particularly activate the hepatocyte-specific properties of hMSCs for developing cell-based therapies in vitro. The transcriptomic analysis further indicated the potential mechanism that TDN-miR122 assisted hMSCs differentiated into functional HLCs. The TDN-miR122-hMSCs exhibited hepatic cell morphology phenotype, significantly up-regulated specific hepatocyte genes and hepatic biofunctions in comparison with the undifferentiated MSCs. Preclinical in vivo transplantation appeared that TDN-miR122-hMSCs in combination with or without TDN could efficiently rescue acute liver failure injury through hepatocyte function supplement, anti-apoptosis, cellular proliferation promotion, and anti-inflammatory. Collectively, our findings may provide a new and facile approach for hepatic differentiation of hMSCs for acute liver failure therapy. Further large animal model explorations are needed to study their potential in clinical translation in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fernández, J., Acevedo, J., Wiest, R., Gustot, T., Amoros, A., Deulofeu, C., Reverter, E., Martínez, J., Saliba, F., Jalan, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314240 · Cited by 572
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
Self-citation
Cited by
Li, F., Wei, H., Jin, Y., Xue, T., Xu, Y., Wang, H., Ju, E., Tao, Y., & Li, M. (2023) · ACS Nano · doi:10.1021/acsnano.3c08495 · Cited by 23
Self-citationMesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?
Zhu, L., Wang, Q., Guo, M., Fang, H., Li, T., Zhu, Y., Jiang, H., Xiao, P., & Hu, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s439974 · Cited by 21
“59 Various liver diseases can lead to hepatic failure, and obtaining a sufficient number of functional hepatocytes is the key to liver regeneration.”
BackgroundSmart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis
Xu, Y., Zhang, Y., Tian, H., Zhong, Q., Yi, K., Li, F., Xue, T., Wang, H., Lao, Y., Xu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202309940 · Cited by 19
Self-citationZou, C.-Y., Han, C., Xiong, M., Hu, J.-J., Jiang, Y.-L., Zhang, X.-Z., Li, Y.-X., Zhao, L.-M., Song, Y.-T., Zhang, Q.-Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.04.005 · Cited by 10
Metadata
- Authors
- Wei, H., Li, F., Xue, T., Wang, H., Ju, E., Li, M., & Tao, Y.
- Venue
- Bioactive Materials
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 28
- Pages
- 50-60
- ISSN
- 2097-1192 (ISSN-L)
- 2452-199X
- OpenAlex
- W4376269173
- Cited by
- 28
- References
- 2
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.